VIC-1911 Monotherapy in Combination With Sotorasib for the Treatment of KRAS G12C-Mutant Non-Small Cell Lung Cancer

Summary

Objectives

Selected subjects will include males and females age =18 years; histologically confirmed
locally advanced or metastatic KRAS G12C-mutated NSCLC; received at least 1 prior line of
cancer therapy with a PD-1 or PD-L1 inhibitor with or without platinum-based
chemotherapy; recovered from all acute toxicities (= Grade 1) due to prior therapy;
adequate renal and hepatic function; and no known history of significant cardiac, hepatic
or ocular disease.

Dose Escalation Phase:

Following screening, a total of up to 36 subjects are anticipated to establish the dose
limiting toxicity (DLT) and maximum tolerated doses (MTDs) of VIC-1911 monotherapy and
VIC-1911 in combination with sotorasib therapy.

Cohort 1a: Subjects who are refractory to or relapsed on prior KRAS G12C inhibitor
therapy will receive VIC-1911 monotherapy. Up to 24 subjects are anticipated in this
cohort.

Cohort 1b: Subjects who are refractory to or relapsed on prior KRAS G12C inhibitor
therapy or are naïve to KRASG12C inhibitor therapy will receive VIC-1911 plus sotorasib
combination therapy. Up to 12 subjects are anticipated in this cohort.

A 3+3 dose escalation schema will be followed to establish the dose limiting toxicity
(DLT) and maximum tolerated dose (MTD) of VIC-1911 and VIC-1911 plus sotorasib
combination. A total of at least 6 subjects will be treated at the MTD in each group
before initiating the Expansion Phase.

Expansion Phase:

Following screening, a total of 104 subjects with KRAS G12C-mutated locally advanced or
metastatic NSCLC are anticipated to expand the disease treatment settings of VIC-1911 as
monotherapy or in combination with sotorasib. VIC-1911 monotherapy and VIC-1911 plus
sotorasib combination therapy will be administered orally at the MTDs established during
the Dose Escalation Phase.

Cohort 2a: Subjects who are refractory to or relapsed on prior KRAS G12C inhibitor
therapy will receive VIC-1911 monotherapy. (n=29)

Cohort 2b: Subjects who are refractory to or relapsed on prior KRAS G12C inhibitor
therapy will receive VIC-1911 plus sotorasib combination therapy.(n=29)

Cohort 2c: Subjects who are naïve to KRAS G12C inhibitor therapy will receive VIC-1911
plus sotorasib combination therapy. (n=46)

VIC-1911 and sotorasib will be taken in the fasted state, 1 hour before or 2 hours after
a meal.

Subjects who demonstrate clinical benefit (CR, PR or SD) will be allowed to continue
therapy with VIC-1911 and sotorasib until progression of disease, observation of
unacceptable adverse events, intercurrent illness or changes in the subject's condition
that prevents further study participation.

Disease response will be assessed according to Response Evaluation Criteria in Solid
Tumors (RECIST v.1.1).

Blood for hematology, coagulation parameters and serum chemistry determinations and urine
will be collected, ECGs will be taken and ophthalmologic exams will be conducted during
the study.

Blood will be taken for PK assessment of VIC-1911 and PD assessment of circulating tumor
DNA biomarker determinations.

Tumor biopsies will be taken from consenting subjects at Screening and on-study for
correlative biomarker determinations. Results will be correlated with clinical outcome.